Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.470 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Enveric Biosciences Participating in BIO-Europe Spring®
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
From Enveric Biosciences
Via Business Wire
Enveric Biosciences CEO Issues Letter to Shareholders
From Enveric Biosciences
Via Business Wire
Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum
Via AB Newswire
Topics Artificial Intelligence Derivatives Intellectual Property
Exposures Artificial Intelligence Derivatives Intellectual Property
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
From Enveric Biosciences
Via Business Wire
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Closing of $5 Million Public Offering
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Pricing of $5 Million Public Offering
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Broad Range of Patent Issuances
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Patent Granted for Drug Candidate
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Participate in BIO International Convention 2024
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
From Enveric Biosciences
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.